Independent report finds ECDC a key support to EU and Member States during infectious disease emergencies
The European Centre for Disease Prevention and Control (ECDC) has a good capacity of quickly reacting to health threats and performing in crisis conditions. It produces products of good professional quality in all areas, has scientific credibility and is generally a source of EU level added value.
The European Centre for Disease Prevention and Control (ECDC) has a good capacity of quickly reacting to health threats and performing in crisis conditions. It produces products of good professional quality in all areas, has scientific credibility and is generally a source of EU level added value. In particular, the Commission and Member States have come to rely on the rapid risk assessments that ECDC produces within 24 to 48 hours of spotting a potential cross-border outbreak. These are among the key strengths of ECDC highlighted in an independent external evaluation of the Centre published today.
The report, by an international consortium of evaluators led by the Bologna based consultancy Economisti Associati, also highlighted a number of operational challenges and areas for further improvement. These include sharpening ECDC’s strategic focus, tailoring its products more to the needs of individual Member States and making it easier to understand “who is responsible for what” within ECDC. Dr Françoise Weber, who was this month re-elected as the Chair of ECDC’s Management Board said: “I congratulate the Centre and its Director on the positive findings of this external evaluation. Over the past decade ECDC has helped the EU and Member States strengthen their defences against epidemics and outbreaks. The Centre has established itself as the hub of a strong network linking the key experts and public health laboratories across Europe. This has proved its value time and again. It is currently a major asset for Europe in responding to the Ebola threat.
At its 18-19 November 2014 meeting in Stockholm ECDC’s Management Board decided to formally accept the final report from the external evaluation and appointed a Drafting Group to develop recommendations for action in response to it. The Group is chaired by the Board member from Belgium, Dr Daniel Reynders and is due to present recommendations for endorsement by the Board in March 2015.
Whole genome sequencing: new ECDC framework suggests priority diseases and implementation options
4 Apr 2019 - Whole genome sequencing (WGS) is a fast-moving technology, but the pace of change vary between pathogens/diseases and European Union countries. In a new report, ECDC proposes to prioritise the implementation of WGS depending on disease and public health application.
Strong laboratory leaders - a key asset for global disease control
28 Mar 2019 - Laboratories play an essential role in the detection, diagnosis, prevention and control of diseases. To strengthen this role, ECDC and five partner organisations have developed the Global Laboratory Leadership Programme (GLLP) to support and sustain national laboratory systems under a One Health approach.
OECD highlights the progress made in laboratory systems in the EU/EEA since the implementation of EULabCap
11 Dec 2018 - The OECD report ‘Health at a Glance: Europe 2018’ summarises the EULabCap indicator results in the chapter on public health laboratory capacity to control infectious disease threats.